Compound: Iclaprim
SMILES: O1c2c(OC)c(OC)cc(c2C=CC1C3CC3)Cc4c(nc(N)nc4)N
InChIKey: HWJPWWYTGBZDEG-UHFFFAOYSA-N
Synonyms: Iclaprim, 192314-93-5, AR-100, 5-[(2-cyclopropyl-7,8-dimethoxy-2h-chromen-5-yl)methyl]pyrimidine-2,4-diamine, RO-48-2622, Iclaprime, 5-((2-Cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl)pyrimidine-2,4-diamine, 42445HUU0O, AR 100, Ro-482622, 2,4-Pyrimidinediamine, 5-[(2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl]-, AR-100.001, RO 48-2622, CHEBI:131751, 5-[(2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl]-2,4-Pyrimidinediamine, 2,4-Pyrimidinediamine, 5-((2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl)-, 5-((2RS)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-ylmethyl)pyrimidine-2,4-diamine, iclaprimum, 5-((2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl)-2,4-Pyrimidinediamine, RefChem:789653, J01EA03, CHEBI:131724, 606-269-6, Mersarex, MFCD09837803, Ro 63-9141;BAL 9141, Iclaprim [INN], AR-101, Iclaprim [USAN], Iclaprim (USAN/INN), Iclaprim [USAN:INN], UNII-42445HUU0O, Iclaprim (Standard), 5-(2-Cyclopropyl-7,8-dimethoxy-2H-chromen-5-ylmethyl)-pyrimidine-2,4-diamine (ICLAPRIM], ICLAPRIM [MI], ICLAPRIM [MART.], ICLAPRIM [WHO-DD], SCHEMBL379386, CHEMBL134561, orb1296194, SCHEMBL12899446, SCHEMBL29462190, SCHEMBL30253885, BDBM18070, GTPL10820, DTXSID70870191, HMS3749A21, EX-A10696, AKOS027422438, CS-7873, DB06358, FI24533, HY-101479R, SB17354, AS-74032, DA-38934, HY-101479, D08337, W16646, Q907480, 5-[(2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl]-2,4-pyrimidine- diamine, 5-[(2-Cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl]-2,4-pyrimidine-diamine, 5-[(2-Cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl]pyrimidine-2,4-diamine, 5-{[(2RS)-2-Cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl]methyl}pyrimidine-2,4-diamine, 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,7-[[(2Z)-2-(5-aMino-1,2,4-thiadiazol-3-yl)-2-(hydroxyiMino)acetyl]aMino]-8-oxo-3-[(E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]Methyl]-,(6R,7R)-
Theoretical properties:
molecular_formula: C19H22N4O3
molecular_weight: 354.4 g/mol
exact_mass: 354.16919058 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 7
rotatable_bond_count: 5
heavy_atom_count: 26
topological_polar_surface_area: 106 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: 5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine is an aminopyrimidine that is 5-methylpyrimidine-2,4-diamine in which one of the hydrogens of the methyl group has been replaced by a 2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl group. It is a member of chromenes, an aminopyrimidine and a member of cyclopropanes.
chebi: An aminopyrimidine that is 5-methylpyrimidine-2,4-diamine in which one of the hydrogens of the methyl group has been replaced by a 2-cyclopropyl-7,8-dimethoxy-2<em>H</em>-chromen-5-yl group.
chembl: ICLAPRIM is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Iclaprim is an antibiotic drug candidate that is active against Gram positive organisms. It is administered intravenously.
In vitro, iclaprim is active against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA), strains of Streptococcus pneumoniae resistant to several common antibiotics, and some Gram-negative bacteria. It is of the diaminopyrimidine dihydrofolate reductase (DHFR)-inhibiting type.